Cel ULTRA-DD (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) will be an European-wide, highly collaborative and inclusive consortium, to validate new targets for drug discovery by (1) generating high quality research tools, with an emphasis on chemical probes; (2) generating the chemical probes in the most cost-effective manner, using structure-guided methods and harnessing the chemical libraries and medicinal chemistry skills of the EFPIA participants; (3) testing the chemical probes in models of human disease based on continuous access to cells from patients with selected inflammatory diseases; and (4) making all reagents and knowledge available to the research community without restriction on use, to expand the impact well beyond the ULTRA-DD partners. In addition to our focus on chemical probes, we will also generate a defined set of antibodies targeting extracellular and membrane bound proteins of relevance to disease. To accomplish the above, ULTRA-DD will create two scientific Cores and formalize a collaborative network of SMEs, academic scientists and clinicians. The Protein Characterization and Tool-Generation Core will comprise four integrated laboratories: University of Oxford’s Structural Genomics Consortium laboratory, led by Chas Bountra (OXF-SGC), ETH in Zurich (ETHZ), led by Ruedi Aebersold, Karolinska Institutet (KI-MBB), led by Susanne Gräslund, and the University of Toronto’s SGC laboratory (UTOR-SGC, will not receive IMI funds), led by Cheryl Arrowsmith, and chemical biology teams in Bayer (Bayer), Janssen (JPNV), Novartis (NOV) and Pfizer (Pfizer). The Clinical Immunology Core will generate high quality assays from patient-derived cells and tissues in selected inflammatory diseases, and test effects of the chemical and antibody probes. This Core comprises the Kennedy Institute (UOXF-KENN) in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford (UOXF-NDORMS), led by Marc Feldmann, the Centre for Molecular Medicine (KI-CMM) at Karolinska Institutet, led by Lars Klareskog and Per-Johan Jakobsson, and DiscoveRx (DRX, Sanj Kumar), an SME based in Birmingham, UK (will not receive IMI funds). The activities within the Cores will be enhanced significantly and the impact of the output expanded dramatically through the involvement of a Collaborative Network of SMEs, IMI projects, academic scientists and Disease Foundations (Appendices 1-3; none of these networks will receive IMI funds). The network will include a Target Prioritization Network (TPN) of top genomicists and clinicians; a Science and Technology Network (STN) that contributes expertise across the ULTRA-DD “gene to chemical probe” pipeline; and an Inflammatory Disease Network (IDN) of clinicians and translational scientists that provides enhanced access to disease-relevant expertise and patient tissue, as well as an expanded array of innovative assays. Each member of the ULTRA-DD network will commit to the open access policy. ULTRA-DD will be managed by the SGC (London, UK), which is a charitable company that has an enviable track record in managing the scientific, legal and financial aspects of open access public-private partnerships. The vision of ULTRA-DD is to create an open access consortium that provides industry with a stream of high quality target-disease associations and tools to study them. Our aspiration is to provide the evidence that convinces industry to launch >10 novel proprietary drug discovery programs based on ULTRA-DD open access output during the course of the project and in the nearest years following completion (2020).ULTRA-DD will meet the deliverables by integrating teams of tool-generating scientists with expert clinicians with access to patient tissue, under an open access, milestone-driven framework, and will expand its output through organized collaborations with innovative European scientists, leading non-European scientists Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesbasic medicinemedicinal chemistrymedical and health sciencesclinical medicineorthopaedics Program(-y) FP7-JTI - Specific Programme "Cooperation": Joint Technology Initiatives Temat(-y) IMI-JU-11-2013-05 - Generation Of Research Tools To Enable The Translation Of Genomic Discoveries Into Drug Discovery Projects Zaproszenie do składania wniosków IMI-JU-11-2013 Zobacz inne projekty w ramach tego zaproszenia System finansowania JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI) Koordynator NOVARTIS PHARMA AG Wkład UE Brak danych Adres LICHTSTRASSE 35 4056 Basel Szwajcaria Zobacz na mapie Region Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Kierownik naukowy Nils Ostermann (Dr) Kontakt administracyjny Stephan Korte (Dr) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych Uczestnicy (9) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko STRUCTURAL GENOMICS CONSORTIUM LBG Zjednoczone Królestwo Wkład UE € 1 353 696,00 Adres EUSTON ROAD 215 NW1 2BE London Zobacz na mapie Region London Inner London — West Camden and City of London Rodzaj działalności Research Organisations Kontakt administracyjny Paul Van Damme (Mr.) Linki Kontakt z organizacją Opens in new window Koszt całkowity Brak danych BAYER AKTIENGESELLSCHAFT Niemcy Wkład UE Brak danych Adres KAISER-WILHELM-ALLEE 1 51373 Leverkusen Zobacz na mapie Region Nordrhein-Westfalen Köln Leverkusen, Kreisfreie Stadt Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Kontakt administracyjny Petra Freitag (Mrs) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych DiscoveRx Corp Ltd Zjednoczone Królestwo Wkład UE Brak danych Adres Faraday Wharf, Innovation Birmingham Campus, Holt Street, Birmingham Science Park Aston B7 4BB Birmingham Zobacz na mapie Kontakt administracyjny Richard Price (Mr) Linki Kontakt z organizacją Opens in new window Koszt całkowity Brak danych EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH Szwajcaria Wkład UE € 1 440 970,00 Adres Raemistrasse 101 8092 Zuerich Zobacz na mapie Region Schweiz/Suisse/Svizzera Zürich Zürich Rodzaj działalności Higher or Secondary Education Establishments Kontakt administracyjny Martin Pestalozzi (Mr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych JANSSEN PHARMACEUTICA NV Belgia Wkład UE Brak danych Adres TURNHOUTSEWEG 30 2340 Beerse Zobacz na mapie Region Vlaams Gewest Prov. Antwerpen Arr. Turnhout Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Kontakt administracyjny Henk Sipma (Mr) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych KAROLINSKA INSTITUTET Szwecja Wkład UE € 4 902 660,00 Adres Nobels Vag 5 17177 Stockholm Zobacz na mapie Region Östra Sverige Stockholm Stockholms län Rodzaj działalności Higher or Secondary Education Establishments Kontakt administracyjny Caroline HAMILTON (Ms.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Zjednoczone Królestwo Wkład UE € 13 502 674,00 Adres WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford Zobacz na mapie Region South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Rodzaj działalności Higher or Secondary Education Establishments Kontakt administracyjny Gill Wells (Ms) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych PFIZER LIMITED Zjednoczone Królestwo Wkład UE Brak danych Adres RAMSGATE ROAD CT13 9NJ Sandwich Zobacz na mapie Region South East (England) Kent East Kent Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Kontakt administracyjny Carla Cox (Dr) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Kanada Wkład UE Brak danych Adres KINGS COLLEGE CIRCLE 27 M5S 1A1 Toronto Zobacz na mapie Rodzaj działalności Higher or Secondary Education Establishments Kontakt administracyjny Arij Al Chawaf (Dr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych